WallStreetZenWallStreetZen

NASDAQ: VNDA
Vanda Pharmaceuticals Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Vanda Pharmaceuticals revenue was $198.77M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $53.2M, up 11.6% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, VNDA annual revenue was $198.8M, with 3.2% growth year-over-year.

VNDA past revenue growth

How has VNDA's revenue growth performed historically?

Company
3.18%
Industry
122.68%
Market
14.46%
VNDA's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
VNDA's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
VNDA's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

VNDA revenue history

Current Revenue
$198.8M
Current Earnings
-$18.9M
Current Profit Margin
-9.5%

Be the first to know when VNDA announces revenue.

VNDA Revenue History By Year

VNDA Yearly RevenueVNDA RevenueVNDA ChangeVNDA Revenue Growth
2024-12-31$198.77M$6.13M+3.18%
2023-12-31$192.64M-$61.74M-24.27%
2022-12-31$254.38M-$14.30M-5.32%
2021-12-31$268.68M$20.51M+8.27%
2020-12-31$248.17M$20.98M+9.23%
2019-12-31$227.19M$34.07M+17.64%
2018-12-31$193.12M$28.04M+16.98%
2017-12-31$165.08M$19.07M+13.06%
2016-12-31$146.02M$36.09M+32.83%
2015-12-31$109.93M$59.77M+119.16%
2014-12-31$50.16M$16.28M+48.05%
2013-12-31$33.88M$1.15M+3.52%
2012-12-31$32.73M$1.46M+4.66%
2011-12-31$31.27M-$4.44M-12.43%
2010-12-31$35.71M$31.16M+685.16%
2009-12-31$4.55MN/AN/A
2008-12-31$0.00N/AN/A
2007-12-31$0.00N/AN/A
2006-12-31$0.00N/AN/A
2005-12-31$0.00-$33.98k-100.00%
2004-12-31$33.98kN/AN/A

1 of 2

Vanda Pharmaceuticals Revenue FAQ

What was VNDA's revenue last quarter?

On Invalid Date, Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q4 2024 revenue of $53.19 million up 17.48% year over year. In the same quarter last year, Vanda Pharmaceuticals's revenue was $45.27 million.

What was Vanda Pharmaceuticals's revenue in 2024?

Vanda Pharmaceuticals's annual revenue for the twelve months ending Dec 31, 2024 was $198.77 million, a 3.18% increase year over year.

How much does Vanda Pharmaceuticals make in a day?

Based on Vanda Pharmaceuticals annual revenue for the past five years, VNDA makes an average of $637,065.21 per day.

What was Vanda Pharmaceuticals's annual revenue growth in the past year?

As of Q1 2025, Vanda Pharmaceuticals's revenue has grown 3.18% year over year. This is 119.5 percentage points lower than the US Biotechnology industry revenue growth rate of 122.68%. Vanda Pharmaceuticals's revenue in the past year totaled $198.77 million.

How much does Vanda Pharmaceuticals make in a year?

Vanda Pharmaceuticals's revenue by year for the past five years is:
  • Vanda Pharmaceuticals's revenue for the twelve months ending Dec 31, 2024 was $198.77 million, a 3.18% increase year over year.
  • Vanda Pharmaceuticals's annual revenue for Dec 31, 2023 was $192.64 million, a 24.27% decrease from 2022.
  • Vanda Pharmaceuticals's annual revenue for 2022 was $254.38 million, a 5.32% decrease from 2021.
  • Vanda Pharmaceuticals's annual revenue for 2021 was $268.68 million, a 8.27% increase from 2020.
  • Vanda Pharmaceuticals's annual revenue for 2020 was $248.17 million, a 9.23% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.